• Firefly Luciferase mRNA (ARCA, 5-moUTP): Next-Gen Assay Reli

  2026-05-25

  Explore how Firefly Luciferase mRNA (ARCA, 5-moUTP) advances assay reliability and translational research through biophysical design and cutting-edge mRNA loading strategies. Discover unique insights on optimizing bioluminescent reporter assays for robust, reproducible results.

• High Viscosity Drives Chemoresistance via P-gp Upregulation

  2026-05-25

  This study demonstrates that high extracellular fluid viscosity in the tumor microenvironment promotes chemoresistance by activating a mechanotransduction cascade that upregulates P-glycoprotein (P-gp). The findings clarify a mechanical basis for drug resistance, highlighting new potential therapeutic strategies to enhance chemotherapy efficacy.

• FXR-KLF11 Axis: CDCA Suppresses JAK2/STAT3 in CI-AKI Models

  2026-05-24

  This study demonstrates that Chenodeoxycholic Acid (CDCA) activates FXR to upregulate KLF11, which in turn suppresses the JAK2/STAT3 pathway, offering significant protection against contrast-induced acute kidney injury (CI-AKI). These mechanistic insights establish the FXR-KLF11 axis as a promising target for renal protection and guide future research in nuclear receptor signaling.

• Evaluating Protease Inhibitor Libraries for Virtual Drug Scr

  2026-05-23

  This article critically reviews the 2022 analysis by Kralj et al., which assessed the design and utility of commercial protease inhibitor libraries for virtual screening and drug discovery. The study identified both the strengths and gaps in current library design, highlighting significant implications for researchers in protease inhibition and related therapeutic fields.

• Plk1-Dependent Regulation of p31comet in Mitotic Checkpoint

  2026-05-22

  This study elucidates how Polo-like kinase 1 (Plk1) regulates the activity of p31comet during mitotic checkpoint complex (MCC) disassembly, revealing a phosphorylation-dependent control mechanism. The findings clarify the balance between MCC assembly and disassembly, with significant implications for understanding mitotic fidelity and potential translational approaches in cell cycle research.

• Topotecan HCl: A Potent Topoisomerase 1 Inhibitor for Oncolo

  2026-05-22

  Topotecan HCl is a validated topoisomerase 1 inhibitor with potent antitumor efficacy. Its ability to stabilize the topoisomerase I-DNA complex induces DNA damage and apoptosis in rapidly dividing tumor cells. This article details its mechanism, evidence, and protocol integration for translational cancer research.

• Lymphodepleting Chemotherapy Primes Tumor Antigenicity for T

  2026-05-21

  Sagie et al. reveal that lymphodepleting chemotherapy enhances the efficacy of neoantigen-directed T cell therapies by remodeling tumor antigen presentation. Through immunoproteasome activation and increased HLA-I expression, chemotherapy synergistically augments T cell-mediated tumor recognition, offering new avenues for improving adoptive cell therapy in solid tumors.

• Optimizing Cardiovascular Research with Nadolol (SQ-11725)

  2026-05-21

  Nadolol (SQ-11725) from APExBIO offers bench scientists a reliable, high-fidelity tool for dissecting beta-adrenergic signaling in hypertension and angina models. This guide translates recent pharmacokinetic insights into actionable workflows and troubleshooting strategies for reproducible results.

• ECL Western Blotting Substrate: Technical Protocol and Best

  2026-05-20

  ECL Western Blotting Substrate (SKU K2187) offers a sensitive, nonradioactive solution for detecting horseradish peroxidase (HRP) in chemiluminescent Western blot assays. It is optimal for protein detection in molecular biology, cancer biology, and signal transduction research, but should not be used for fluorescent or radioisotopic workflows.

• Sequencing Therapies in Waldenström Macroglobulinemia: Genom

  2026-05-20

  This review critically examines evolving approaches to treatment sequencing in Waldenström macroglobulinemia, emphasizing the integration of MYD88 and CXCR4 mutational status into regimen selection. The findings highlight the importance of genomic profiling and personalized therapy, setting a new framework for clinical decision-making in this rare lymphoma.

• GS-441524 Prodrug: Mechanistic Insights and Assay Impact

  2026-05-19

  Explore the mechanistic foundations and translational impact of GS-441524 prodrug research for antiviral development. This article offers a unique, in-depth analysis of GS-441524's conversion pathways, pharmacokinetics, and assay considerations, advancing beyond conventional workflow summaries.

• Lymphodepleting Chemotherapy Enhances T Cell Therapy via Ant

  2026-05-19

  This study demonstrates that lymphodepleting chemotherapy, including DNA synthesis inhibitors, can significantly boost the efficacy of neoantigen-directed adoptive T cell therapies by remodeling the tumor antigenic landscape. Enhanced immunoproteasome activity and HLA-I upregulation together facilitate better tumor recognition and killing by T cells, with direct implications for the optimization of immunotherapy regimens.

• Topotecan HCl: Applied Workflows for Antitumor and DNA Damag

  2026-05-18

  Topotecan HCl stands out as a topoisomerase 1 inhibitor validated for both cancer cytotoxicity and mechanistic DNA damage studies. This guide translates latest reference findings and peer-driven workflows into actionable, optimized lab protocols for tumor and neuroinflammation models.

• Phebestin as a Potent Aminopeptidase Inhibitor in Malaria Mo

  2026-05-18

  This study identifies phebestin, a bestatin-related aminopeptidase inhibitor, as a highly effective antiplasmodial agent with nanomolar potency against both chloroquine-sensitive and -resistant Plasmodium falciparum strains. These findings provide a foundation for targeting peptidase-mediated pathways in malaria therapy and highlight the value of structurally informed drug design.

• Z-WEHD-FMK: Advanced Caspase Inhibition for Inflammation Res

  2026-05-17

  Z-WEHD-FMK (Z-Trp-Glu(OMe)-His-Asp(OMe)-FMK) delivers precise, irreversible inhibition of inflammatory caspases for dissecting cell signaling in pyroptosis, apoptosis, and infectious disease models. This guide translates cutting-edge findings—including HOXC8’s regulation of pyroptosis—into actionable protocols and troubleshooting strategies, maximizing the impact of APExBIO’s caspase inhibitor in advanced research workflows.

15854 records 1/1057 page Next 12345 下5页 Last page